Oleg Ursu
Oleg Ursu
Adresă de e-mail confirmată pe vrtx.com
Citat de
Citat de
A comprehensive map of molecular drug targets
R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ...
Nature reviews Drug discovery 16 (1), 19-34, 2017
BDDCS, the Rule of 5 and drugability
LZ Benet, CM Hosey, O Ursu, TI Oprea
Advanced drug delivery reviews 101, 89-98, 2016
Unexplored therapeutic opportunities in the human genome
TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ...
Nature reviews Drug discovery 17 (5), 317-332, 2018
Drug repurposing from an academic perspective
TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ...
Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011
DrugCentral: online drug compendium
O Ursu, J Holmes, J Knockel, CG Bologa, JJ Yang, SL Mathias, SJ Nelson, ...
Nucleic acids research, gkw993, 2016
Pharos: collating protein information to shed light on the druggable genome
DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, ...
Nucleic acids research 45 (D1), D995-D1002, 2017
Understanding drug‐likeness
O Ursu, A Rayan, A Goldblum, TI Oprea
Wiley Interdisciplinary Reviews: Computational Molecular Science 1 (5), 760-781, 2011
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe
L Hong, SR Kenney, GK Phillips, D Simpson, CE Schroeder, J Nöth, ...
Journal of Biological Chemistry 288 (12), 8531-8543, 2013
Probe reports from the nih molecular libraries program
Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ...
Bethesda (MD), 2010
DrugCentral 2021 supports drug discovery and repositioning
S Avram, CG Bologa, J Holmes, G Bocci, TB Wilson, DT Nguyen, ...
Nucleic acids research 49 (D1), D1160-D1169, 2021
A potent and selective inhibitor of Cdc42 GTPase
Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ...
Probe Reports from the NIH Molecular Libraries Program [Internet], 2010
A crowdsourcing evaluation of the NIH chemical probes
TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ...
Nature chemical biology 5 (7), 441-447, 2009
DrugCentral 2018: an update
O Ursu, J Holmes, CG Bologa, JJ Yang, SL Mathias, V Stathias, ...
Nucleic acids research 47 (D1), D963-D970, 2019
Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer‐aided drug repurposing
TI Oprea, SK Nielsen, O Ursu, JJ Yang, O Taboureau, SL Mathias, ...
Molecular informatics 30 (2‐3), 100-111, 2011
A Competitive Nucleotide Binding Inhibitor: In Vitro Characterization of Rab7 GTPase Inhibition
JO Agola, L Hong, Z Surviladze, O Ursu, A Waller, JJ Strouse, ...
ACS chemical biology 7 (6), 1095-1108, 2012
Badapple: promiscuity patterns from noisy evidence
JJ Yang, O Ursu, CA Lipinski, LA Sklar, TI Oprea, CG Bologa
Journal of cheminformatics 8, 1-14, 2016
Omega polynomial in tubular nanostructures
MV Diudea, S Cigher, AE Vizitiu, O Ursu, PE John
Croatica chemica acta 79 (3), 445-448, 2006
Drug target ontology to classify and integrate drug discovery data
Y Lin, S Mehta, H Küçük-McGinty, JP Turner, D Vidovic, M Forlin, A Koleti, ...
Journal of biomedical semantics 8, 1-16, 2017
Emerging trends in the discovery of natural product antibacterials
CG Bologa, O Ursu, TI Oprea, CE Melançon III, GP Tegos
Current Opinion in Pharmacology 13 (5), 678-687, 2013
Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters
JJ Strouse, I Ivnitski-Steele, A Waller, SM Young, D Perez, AM Evangelisti, ...
Analytical biochemistry 437 (1), 77-87, 2013
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20